- AST and Marchesini Group have formed a strategic partnership to expand capabilities in sterile fill-finish production.
- Marchesini Group has acquired a 44.39% equity stake in AST, strengthening collaboration across global manufacturing and packaging networks.
AST has entered a strategic partnership with the Marchesini Group to enhance global capabilities in sterile fill-finish and drug product manufacturing. The companies said the agreement combines technology, expertise, and distribution infrastructures to deliver more integrated solutions across major global regions.
Under the partnership, AST’s Chairman and CEO, Joe Hoff, will increase his ownership stake in the organisation and will join the steering committee of the Aseptic Division of the Marchesini Group. Hoff will continue to serve as Chairman and CEO of AST.
“This partnership isn’t about changing who we are—it’s about leveraging our relationships, experiences, capabilities and resources to accelerate our shared leadership in drug product manufacturing and sterile fill-finish.”
AST’s Chairman and CEO, Joe Hoff
Marchesini Group has acquired a 44.39% equity stake in AST, expanding its aseptic technology portfolio. The company noted that AST’s advanced filling and closing systems will complement existing capabilities at Corima and MAR, its two Italian production sites focused on sterile product filling and precision technologies. Maurizio Marchesini, President of Marchesini Group, said the investment supports the company’s strategy to build partnerships that expand its offering of advanced solutions.
Both organisations described the partnership as a means to increase production capacity, enhance global support networks and strengthen market presence. They stated that the alliance will support development of new technologies to meet growing demand for specialised aseptic systems in pharmaceutical and biotech manufacturing.
Valerio Soli, CEO of Marchesini Group, said the collaboration will help the group deepen expertise in customised aseptic systems and broaden its presence in the U.S. market. The companies noted that the partnership aligns with a long-term commitment to operational excellence and innovation across sterile manufacturing.
